Korean CDMO Samsung BioLogics will open labs in either the Boston or San Francisco area early 2020 on the back of demand for its development services. In 2017, Samsung BioLogics added the ‘D’ to its contract development and manufacturing organization (CDMO) credentials by announcing plans to offer customers cell line and process development (PD) services on top of its well-established clinical and commercial production services. In the 18 months since launching these services, the South Korean firm has undertaken 33…